Insider Transactions in Q1 2023 at Madrigal Pharmaceuticals, Inc. (MDGL)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2023
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
5,000
-14.33%
|
$1,370,000
$274.93 P/Share
|
|
Mar 01
2023
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+31.91%
|
$435,000
$87.92 P/Share
|
|
Feb 28
2023
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
5,000
-25.21%
|
$1,355,000
$271.66 P/Share
|
|
Feb 28
2023
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+31.91%
|
$435,000
$87.92 P/Share
|
|
Jan 30
2023
|
Fred B Craves Director |
SELL
Bona fide gift
|
Indirect |
3,557
-5.87%
|
-
|
|
Jan 17
2023
|
Richard S Levy |
SELL
Open market or private sale
|
Direct |
22,489
-11.15%
|
$6,544,299
$291.63 P/Share
|
|
Jan 17
2023
|
Richard S Levy |
BUY
Exercise of conversion of derivative security
|
Direct |
22,489
+30.35%
|
$2,293,878
$102.76 P/Share
|
|
Jan 16
2023
|
Paul A Friedman |
SELL
Payment of exercise price or tax liability
|
Direct |
2,254
-10.13%
|
$547,722
$243.92 P/Share
|
|
Jan 16
2023
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
20,001
+50.0%
|
-
|
|
Jan 16
2023
|
Paul A Friedman |
BUY
Grant, award, or other acquisition
|
Direct |
26,668
+50.0%
|
-
|
|
Jan 16
2023
|
Alex G. Howarth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,001
+50.0%
|
-
|
|
Jan 16
2023
|
Brian Joseph Lynch SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
15,001
+50.0%
|
-
|
|
Jan 16
2023
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
5,667
+50.0%
|
-
|
|
Jan 16
2023
|
Remy Sukhija Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,001
+50.0%
|
-
|
|
Jan 03
2023
|
Brian Joseph Lynch SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
13,000
-40.01%
|
$3,679,000
$283.18 P/Share
|
|
Jan 03
2023
|
Brian Joseph Lynch SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
13,000
+50.0%
|
$1,183,000
$91.79 P/Share
|